Biotech · Private company
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Track this companyFree. Adds BioNTech (Shanghai) Pharmaceuticals Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials55 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials5
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate CancerPHASE3 · RECRUITING · started Apr 22, 2026ClinicalTrials.gov NCT07365995 · fetched Nov 12, 2026
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPHASE1_PHASE2 · RECRUITING · started Aug 12, 2025ClinicalTrials.gov NCT07070232 · fetched Nov 12, 2026
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerPHASE3 · RECRUITING · started Jun 10, 2025ClinicalTrials.gov NCT06340568 · fetched Nov 12, 2026
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerPHASE1_PHASE2 · RECRUITING · started Apr 23, 2025ClinicalTrials.gov NCT06827236 · fetched Nov 12, 2026
- Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line TreatmentPHASE2 · RECRUITING · started Mar 3, 2025ClinicalTrials.gov NCT06841055 · fetched Nov 12, 2026